Tags:BioTechCenterDevelopmentHealthTechHumanITMedTechPlatformProductTechnology
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.
Location: United States, California, San Diego
Member count: 11-50
Total raised: $22M
Founded date: 2005

Investors 3

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
05.08.2016Grant$2M--
14.10.2014Series B$20M-socaltech....

Mentions in press and media 13

DateTitleDescriptionCategoryAuthorSource
14.09.2021DNAtrix An... HOUSTON, Sept. 14, 2021 /PRN...--prnewswire...
11.02.2021DNAtrix An... HOUSTON, Feb. 11, 2021 /PRNe...--prnewswire...
20.11.2020DNAtrix An... HOUSTON, Nov. 20, 2020 /PRNe...--prnewswire...
09.11.2020DNAtrix An... HOUSTON, Nov. 9, 2020 /PRNew...--prnewswire...
24.10.2014Funding Ro...$4.1 million in equity raised ...--medcitynew...
14.10.2014DNAtrix Co... SAN DIEGO, CA, Clinical-stag...--vcnewsdail...
14.10.2014DNAtrix Co...DNAtrix, a Houston, Texas and ...USA-finsmes.co...
14.10.2014 DNAtri...San Diego-based DNAtrix, which...--socaltech....
16.01.2014Potential ...While some pharmaceutical and ...--medcitynew...
17.08.2012Brain canc...Initially, the drug is being s...--medcitynew...
Show more